CNS DRUGS

CNS Drugs is a prestigious international peer-reviewed journal dedicated to the comprehensive advancement of central nervous system (CNS) pharmacology and therapeutics, published by Adis International Ltd under the Springer Nature umbrella and based in New Zealand. Identified by the ISSN 1172-7047, this monthly publication serves as a critical resource for researchers and clinicians, maintaining a strong standing in the scientific community with an impact factor that consistently places it within the higher quartiles of the medical and pharmaceutical sciences, as reflected in its SCI indexing and favorable CAS journal rankings. The journal’s scope rigorously encompasses both clinical and basic research, with a particular emphasis on pharmacology, pharmacotherapy, drug safety, and the development of novel agents for the management of psychiatric disorders, neurodegenerative diseases, and chronic pain. By prioritizing high-quality original investigations and authoritative reviews, CNS Drugs upholds strict editorial standards that ensure the novelty and clinical relevance of the published work, thereby establishing itself as a leading reference in the field. Although the journal operates on a traditional subscription model rather than open access, its robust academic reputation and competitive selection process make it a highly desirable venue for scholars seeking to disseminate impactful research to a global audience of neuroscientists, pharmacologists, and medical professionals.